Related Experiment Video

Updated: Jun 18, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Hsp90 inhibitors as promising agents for radiotherapy

Alexander E Kabakov1, Vladimir A Kudryavtsev, Vladimir L Gabai

  • 1Department of Radiation Biochemistry, Medical Radiology Research Center, Obninsk, Russia. aekabakov@hotmail.com

Journal of Molecular Medicine (Berlin, Germany)
|December 1, 2009
PubMed

Insights

Heat shock protein 90 (Hsp90) inhibitors destabilize cancer cell proteins, enhancing tumor sensitivity to radiation therapy. This review explores Hsp90 inhibitors for improved radiotherapy outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Heat shock protein 90 (Hsp90) is a molecular chaperone crucial for cancer cell survival and drug resistance.
  • Hsp90 client proteins are involved in signaling pathways promoting tumor growth and therapeutic resistance.

Purpose of the Study:

  • To review the role of Hsp90 inhibitors in sensitizing human tumors to radiotherapy.
  • To discuss the molecular mechanisms and selectivity of Hsp90 inhibition-induced radiosensitization.

Main Methods:

  • Review of preclinical and clinical data on Hsp90 inhibitors.
  • Analysis of molecular mechanisms underlying Hsp90 inhibition and radiosensitization.

Main Results:

  • Hsp90 inhibition leads to destabilization and degradation of client proteins essential for tumor cell survival.
  • Hsp90 inhibitors demonstrate potential in sensitizing tumors to irradiation, improving radiotherapy efficacy.

Conclusions:

  • Pharmacological Hsp90 inhibitors represent a promising strategy to enhance radiotherapy outcomes in cancer treatment.
  • Further research into Hsp90 inhibition mechanisms can optimize its application in combination cancer therapies.

More Related Videos

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...